Effects of 2 Different Doses of Pantoprazole on Gastric pH and Recurrent Bleeding in Patients Who Bled From Peptic Ulcers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00279123|
Recruitment Status : Completed
First Posted : January 19, 2006
Last Update Posted : January 19, 2006
Endoscopic treatment of bleeding peptic ulcers is effective to prevent rebleeding. Adjuvant medical treatment to increase gastric pH may further decrease rebleeding. Recent studies on potent acid suppression by proton pump inhibitors (PPI) demonstrated the efficacy in preventing rebleeding. Lau demonstrated that high dose intravenous infusion of omeprazole decreased rebleeding in peptic ulcers with stigmata of recent hemorrhage.
There is little data regarding the effect of pantoprazole on bleeding peptic ulcers. Furthermore, the optimal dose of PPI is unknown. Few studies have included measurement of gastric pH in addition to clinical outcome.
This study compares the effect of two doses of intravenous pantoprazole with no acid suppression in bleeding peptic ulcers after endoscopic therapy. In addition to the usual clinical endpoints, gastric pH is monitored to study the relation of pH elevation and the clinical outcome.
|Condition or disease||Intervention/treatment||Phase|
|Peptic Ulcer Hemorrhage||Drug: pantoprazole infusion Drug: pantoprazole bolus Drug: no treatment||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||January 2002|
- Rebleeding rate within 30 days after endoscopic therapy
- Transfusion requirement
- duration of hospital stay
- need for operative intervention
- mortality rate
- gastric pH
- side effects of pantoprazole
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00279123
|Department of Surgery, Kwong Wah Hospital|
|Hong Kong, China|
|Principal Investigator:||Wai-ka Hung, MBBS||Department of Surgery, Kowng Wah Hospital|